Celularity (CELU) Competitors $3.94 +0.09 (+2.34%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$3.76 -0.18 (-4.44%) As of 08/29/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELU vs. INBX, ADCT, CTMX, ALDX, BNTC, TNXP, FDMT, AMRN, ZYBT, and CADLShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Inhibrx Biosciences (INBX), ADC Therapeutics (ADCT), CytomX Therapeutics (CTMX), Aldeyra Therapeutics (ALDX), Benitec Biopharma (BNTC), Tonix Pharmaceuticals (TNXP), 4D Molecular Therapeutics (FDMT), Amarin (AMRN), Zhengye Biotechnology (ZYBT), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. Celularity vs. Its Competitors Inhibrx Biosciences ADC Therapeutics CytomX Therapeutics Aldeyra Therapeutics Benitec Biopharma Tonix Pharmaceuticals 4D Molecular Therapeutics Amarin Zhengye Biotechnology Candel Therapeutics Celularity (NASDAQ:CELU) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Do analysts rate CELU or INBX? Celularity currently has a consensus price target of $6.00, indicating a potential upside of 52.28%. Given Celularity's higher probable upside, equities research analysts plainly believe Celularity is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inhibrx Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer CELU or INBX? In the previous week, Celularity had 1 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 5 mentions for Celularity and 4 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.95 beat Celularity's score of 0.12 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CELU or INBX more profitable? Inhibrx Biosciences has a net margin of 0.00% compared to Celularity's net margin of -165.22%. Inhibrx Biosciences' return on equity of -137.83% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Celularity-165.22% -564.17% -56.34% Inhibrx Biosciences N/A -137.83%-76.31% Which has higher earnings and valuation, CELU or INBX? Inhibrx Biosciences has lower revenue, but higher earnings than Celularity. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelularity$54.22M1.74-$57.89M-$2.65-1.49Inhibrx Biosciences$200K2,041.68$1.69B-$10.58-2.67 Which has more risk & volatility, CELU or INBX? Celularity has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Do insiders & institutionals have more ownership in CELU or INBX? 19.0% of Celularity shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 22.1% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryCelularity and Inhibrx Biosciences tied by winning 7 of the 14 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.36M$3.07B$5.75B$9.76BDividend YieldN/A2.29%4.08%4.04%P/E RatioN/A20.7883.2726.60Price / Sales1.74386.53541.17113.73Price / CashN/A44.2237.4459.26Price / Book10.658.0710.556.58Net Income-$57.89M-$53.98M$3.27B$265.95M7 Day Performance3.96%-0.88%0.40%0.17%1 Month Performance20.12%7.72%7.31%3.90%1 Year Performance27.92%7.03%46.58%19.67% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity0.5643 of 5 stars$3.94+2.3%$6.00+52.3%+27.9%$94.36M$54.22M0.00220Earnings ReportINBXInhibrx Biosciences1.5903 of 5 stars$25.04+0.2%N/A+93.7%$362.13M$1.40M-2.37166ADCTADC Therapeutics1.2937 of 5 stars$3.09-3.0%$7.75+151.2%+6.0%$357.75M$70.84M-1.96310CTMXCytomX Therapeutics4.189 of 5 stars$2.00-5.7%$5.75+187.5%+72.9%$349.61M$138.10M3.57170News CoverageALDXAldeyra Therapeutics1.6581 of 5 stars$5.77-0.7%$9.50+64.6%+1.5%$347.99MN/A-6.7910News CoverageBNTCBenitec Biopharma1.4721 of 5 stars$13.21+1.7%$26.00+96.8%+43.1%$340.99M$80K-8.7520Positive NewsTNXPTonix Pharmaceuticals2.9061 of 5 stars$34.59-8.9%$70.00+102.4%+29.4%$332.93M$10.09M-0.8850FDMT4D Molecular Therapeutics2.3022 of 5 stars$6.74-4.9%$30.40+351.0%-59.0%$331.12M$40K-1.91120Analyst ForecastAMRNAmarin0.2246 of 5 stars$15.39-3.7%$12.00-22.0%+20.2%$330.90M$228.61M-4.19360News CoverageZYBTZhengye BiotechnologyN/A$8.00+14.6%N/AN/A$329.22M$25.53M0.00278News CoverageGap DownCADLCandel Therapeutics2.4427 of 5 stars$5.71-4.0%$22.00+285.3%-14.2%$326.63M$120K-8.2860News CoveragePositive News Related Companies and Tools Related Companies INBX Competitors ADCT Competitors CTMX Competitors ALDX Competitors BNTC Competitors TNXP Competitors FDMT Competitors AMRN Competitors ZYBT Competitors CADL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELU) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
